Evidence map›Paper›PMID 30177664›Full record

ArticleMolecules (Basel, Switzerland)2018

Ferrocene-Containing Impiridone (ONC201) Hybrids: Synthesis, DFT Modelling, In Vitro Evaluation, and Structure⁻Activity Relationships.

Péter Bárány, Rita Szabó Oláh, Imre Kovács, Tamás Czuczi, Csenge Lilla Szabó, Angéla Takács, Eszter Lajkó, Orsolya Láng, László Kőhidai, Gitta Schlosser and 4 more

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Péter BárányInstitute of Chemistry, Eötvös Loránd University (ELTE), Budapest, H-1117 Budapest, Hungary. peterbarany@caesar.elte.hu.
Rita Szabó OláhMTA-ELTE Research Group of Peptide Chemistry, Budapest Pázmány P. sétány 1/A, H-1117 Budapest, Hungary. rita.olah.szabo@gmail.com.ORCID 0000-0001-9208-7251
Imre KovácsInstitute of Chemistry, Eötvös Loránd University (ELTE), Budapest, H-1117 Budapest, Hungary. kimre950518@gmail.com.
Tamás CzucziInstitute of Chemistry, Eötvös Loránd University (ELTE), Budapest, H-1117 Budapest, Hungary. czuczi.tamas@gmail.com.
Csenge Lilla SzabóInstitute of Chemistry, Eötvös Loránd University (ELTE), Budapest, H-1117 Budapest, Hungary. szabo.csenge44@gmail.com.
Angéla TakácsDepartment of Genetics, Cell and Immunobiology, Semmelweis University, Nagyvárad tér 4, H-1089 Budapest, Hungary. angela.takacs1@gmail.com.
Eszter LajkóDepartment of Genetics, Cell and Immunobiology, Semmelweis University, Nagyvárad tér 4, H-1089 Budapest, Hungary. lajesz@gmail.com.
Orsolya LángDepartment of Genetics, Cell and Immunobiology, Semmelweis University, Nagyvárad tér 4, H-1089 Budapest, Hungary. langorsi@gmail.com.
László KőhidaiDepartment of Genetics, Cell and Immunobiology, Semmelweis University, Nagyvárad tér 4, H-1089 Budapest, Hungary. kohlasz2@gmail.com.
Gitta SchlosserInstitute of Chemistry, Eötvös Loránd University (ELTE), Budapest, H-1117 Budapest, Hungary. gitta.schlosser@gmail.com.ORCID 0000-0002-7637-7133
Szilvia BőszeMTA-ELTE Research Group of Peptide Chemistry, Budapest Pázmány P. sétány 1/A, H-1117 Budapest, Hungary. szilvia.bosze@gmail.com.
Gábor MezőMTA-ELTE Research Group of Peptide Chemistry, Budapest Pázmány P. sétány 1/A, H-1117 Budapest, Hungary. gmezo@caesar.elte.hu.
Ferenc HudeczInstitute of Chemistry, Eötvös Loránd University (ELTE), Budapest, H-1117 Budapest, Hungary. fhudecz@caesar.elte.hu.
Antal CsámpaiInstitute of Chemistry, Eötvös Loránd University (ELTE), Budapest, H-1117 Budapest, Hungary. csampai@caesar.elte.hu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inspired by the well-established clinical evidence about the interplay between apoptotic TRAIL (tumour necrosis factor-related apoptosis-inducing ligand) mechanism and reactive oxygen species (ROS)-mediated oxidative stress, a set of novel ONC201 hybrids containing the impiridone core and one or two differently positioned ferrocenylalkyl groups were synthesised in our present work. These two types of residues have been implicated in the aforementioned mechanisms associated with cytotoxic activity. A straightforward, primary amine-based synthetic approach was used allowing the introduction of a variety of

Indexed as

Antineoplastic AgentsBenzyl CompoundsCell Line, TumorCell ProliferationCell SurvivalFerrous CompoundsHeterocyclic Compounds, 4 or More RingsHT29 CellsHumansImidazolesMetallocenesModels, MolecularPyridinesPyrimidinesReactive Oxygen SpeciesStructure-Activity RelationshipAntineoplastic AgentsBenzyl CompoundsferroceneFerrous CompoundsHeterocyclic Compounds, 4 or More RingsImidazolesMetallocenesPyridinesPyrimidinesReactive Oxygen SpeciesTIC10 compoundbioorganometallic chemistrycytotoxic activityDFT calculationsferroceneNMR spectroscopyorganic synthesisstructure–activity relationships

Identifiers

PMID30177664
PMCPMC6225426

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.